Adaptimmune Therapeutics plc announced that Adrian Rawcliffe, currently Chief Financial Officer of the company, will succeed James Noble as Chief Executive Officer. James will retire from his executive duties and transition to a non-executive director role on the company’s board on September 1, 2019. Adrian will join the board of directors on this date.   “Following James’ request early last year, the Board has been planning for leadership succession. Today, I am pleased to announce Adrian’s a...